Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03934840 · ClinicalTrials.gov registry record · Phase 2
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone
A Phase 2 study of Prostate Cancer, sponsored by Masonic Cancer Center, University of Minnesota.
- Active
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 8
- Study locations
NCT03934840: Active Phase 2 study of Prostate Cancer, sponsored by Masonic Cancer Center, University of Minnesota.
NCT03934840 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 22 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03934840, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by Masonic Cancer Center, University of Minnesota.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 8
- Study locations
Study Summary
This is a phase II clinical trial in patients with metastatic castration sensitive prostate cancer. The objective of the study is to determine the efficacy and further define the safety of the treatment combination. This study will evaluate dose levels of carboplatin AUC 4 with cabazitaxel 20 mg/m2. Patients will be treated with the combination of ADT and carboplatin and cabazitaxel for 6 cycles. After 6 cycles of chemotherapy, they will start abiraterone with ADT. The primary objective is to determine the percent of subjects that have no PSA or radiographic progression at 1 year. Secondary objectives will include determining the progression-free survival, time to PSA nadir and time to PSA progression of carboplatin and cabazitaxel in combination with ADT.
Primary Outcome
Number of patients who have no PSA or radiographic progression as determined by RECIST 1.1 or PCWG3 criteria
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Prednisone
- DRUG Abiraterone
- DRUG Cabazitaxel
Study Locations (8)
Illinois
- Northwestern University - Chicago
- University of Chicago - Chicago
Arizona
- Mayo Clinic Arizona - Phoenix
Louisiana
- Tulane University - New Orleans
Minnesota
- Masonic Cancer Center at University of Minnesota - Minneapolis
Nevada
- Comprehensive Cancer Centers of Nevada - Las Vegas
Pennsylvania
- Thomas Jeferson University - Philadelphia
Rhode Island
- Lifespan Cancer Institute - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2019-10-10 |
| Est. Completion | 2025-05 |
| Phase | Phase 2 |
What the registry record for NCT03934840 still lists
NCT03934840 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Carboplatin is the first listed.
NCT03934840 lists 8 locations in 7 states (Illinois, Arizona, Louisiana).
Frequently Asked Questions
What is clinical trial NCT03934840 about?
NCT03934840 is a clinical study titled "CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone". This is a phase II clinical trial in patients with metastatic castration sensitive prostate cancer. The objective of the study is to determine the efficacy and further define the safety of the treatment combination. This study will evaluate dose levels of carboplatin AUC 4 with cabazitaxel 20 mg/m2....
What is the current status of trial NCT03934840?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2019-10-10. Estimated completion is 2025-05.
What conditions does trial NCT03934840 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT03934840?
The interventions under investigation include: Carboplatin (DRUG), Prednisone (DRUG), Abiraterone (DRUG), Cabazitaxel (DRUG).
Who is sponsoring clinical trial NCT03934840?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03934840 being conducted?
This trial has 8 study locations across Arizona, Illinois, Louisiana, Minnesota, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03934840's enrollment target sits among peer trials
22 645th of 735 higher than 91 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI